These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents. Gjerden P, Slørdal L, Bramness JG. Eur J Clin Pharmacol; 2009 Dec; 65(12):1229-35. PubMed ID: 19644682 [Abstract] [Full Text] [Related]
26. Anticholinergic properties of antipsychotic drugs and their relation to extrapyramidal side-effects. Sayers AC, Bürki HR, Ruch W, Asper H. Psychopharmacology (Berl); 1976 Dec 21; 51(1):15-22. PubMed ID: 13446 [Abstract] [Full Text] [Related]
35. Radioreceptor assay of neuroleptics in refractory chronic schizophrenic patients. Lindenmayer JP, Smith D, Katz I. J Clin Psychiatry; 1984 Mar 21; 45(3):117-9. PubMed ID: 6142035 [Abstract] [Full Text] [Related]
36. Acute extrapyramidal syndrome in Cebus monkeys: development mediated by dopamine D2 but not D1 receptors. Coffin VL, Latranyi MB, Chipkin RE. J Pharmacol Exp Ther; 1989 Jun 21; 249(3):769-74. PubMed ID: 2567351 [Abstract] [Full Text] [Related]
37. Neuroleptic and anticholinergic drug use in Chinese patients with schizophrenia resident in a state psychiatric hospital in Singapore. Chong SA, Sachdev P, Mahendran R, Chua HC. Aust N Z J Psychiatry; 2000 Dec 21; 34(6):988-91. PubMed ID: 11127630 [Abstract] [Full Text] [Related]
38. A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Theoretical implications for potency differences among neuroleptics. Singh MM, Kay SR. Psychopharmacologia; 1975 Aug 21; 43(2):103-13. PubMed ID: 1103205 [Abstract] [Full Text] [Related]